Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Drug Dosage Regimen: Overview01:15

Drug Dosage Regimen: Overview

A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Retroviruses02:33

Retroviruses

Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
Inhibitors Of Virion Release01:25

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

How to Identify and Treat MetALD.

Gastroenterology & hepatology·2026
Same author

Increased Risk for Liver Disease in Patients With Chronic Hepatitis B Virus Infection and Low-Level Viraemia.

Alimentary pharmacology & therapeutics·2026
Same author

Evaluation of Abnormal Liver Biochemical Test Results.

Gastroenterology·2026
Same author

A systematic review of post-liver transplantation treatment and outcomes for late T-cell mediated, chronic ductopenic, and antibody-mediated rejection.

Hepatology communications·2026
Same author

International Expert Delphi Consensus on Endoscopic Ultrasound-guided Portosystemic Pressure Gradient: Best Practices and Future Directions.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2025
Same author

Multi-Society Expert Panel Consensus Guidance Regarding Clinical Assessment and Clinical Trial Endpoints in Adults With Alpha-1 Antitrypsin Deficiency-Associated Liver Disease.

Gastroenterology·2025
Same journal

Metabolic Dysfunction-Associated Steatohepatitis: From Fibrosis-Based Risk Stratification to Emerging Therapeutic Strategies.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease and Viral Hepatitis.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction Associated Steatohepatitis (MASH) in Oceania, Central America, and the Caribbean.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease in Latin America.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease in Africa: From Burden to Action.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease in Asia: Epidemiology, Clinical Features, and Management.

Clinics in liver disease·2026
See all related articles

Related Experiment Video

Updated: May 29, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Boceprevir: a user's guide.

Paul Y Kwo1, Rong Zhao

  • 1Liver Transplantation, Gastroenterology/Hepatology Division, Indiana University School of Medicine, Indianapolis, IN 46202-5121, USA. pkwo@iupui.edu

Clinics in Liver Disease
|August 27, 2011
PubMed
Summary
This summary is machine-generated.

Boceprevir, a hepatitis C virus (HCV) NS3 protease inhibitor, enhances standard therapy, improving sustained virological response and shortening treatment duration for genotype-1 infections.

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Safety Precautions and Operating Procedures in an (A)BSL-4 Laboratory: 2. General Practices
08:53

Safety Precautions and Operating Procedures in an (A)BSL-4 Laboratory: 2. General Practices

Published on: October 3, 2016

Related Experiment Videos

Last Updated: May 29, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Safety Precautions and Operating Procedures in an (A)BSL-4 Laboratory: 2. General Practices
08:53

Safety Precautions and Operating Procedures in an (A)BSL-4 Laboratory: 2. General Practices

Published on: October 3, 2016

Area of Science:

  • Hepatology
  • Virology
  • Drug Development

Background:

  • The hepatitis C virus (HCV) NS3/4A serine protease is crucial for viral replication.
  • It is a primary target for developing antiviral therapies against HCV.
  • Boceprevir is an NS3 protease inhibitor investigated for HCV treatment.

Purpose of the Study:

  • To review the mechanism of action of boceprevir.
  • To discuss the effects of boceprevir on hepatitis C virus.
  • To examine viral resistance to boceprevir.

Main Methods:

  • Literature review of studies on boceprevir and HCV.
  • Analysis of clinical data regarding boceprevir efficacy.
  • Examination of virological and resistance data.

Main Results:

  • Boceprevir, when added to peginterferon and ribavirin, improves sustained virological response in genotype-1 HCV.
  • Treatment duration is shortened in individuals receiving boceprevir.
  • Understanding boceprevir's mechanism and resistance is key.

Conclusions:

  • Boceprevir shows promise as an effective component of HCV therapy.
  • The NS3 protease inhibitor offers improved outcomes for genotype-1 HCV patients.
  • Further research into resistance mechanisms is warranted.